- Home
- INMB
as 07-26-2024 4:00pm EST
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Upcoming Earnings Alert:
Get ready for potential market movements as INmune Bio Inc. Common stock INMB prepares to release earnings report on 01 Aug 2024.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 200.0M | IPO Year: | 2019 |
| Target Price: | N/A | AVG Volume (30 days): | 222.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.50 - $14.74 | Next Earning Date: | 08-01-2024 |
| Revenue: | $131,000 | Revenue Growth: | -47.39% |
| Revenue Growth (this year): | -80.7% | Revenue Growth (next year): | 2.28% |
Stock Insider Trading Activity of INmune Bio Inc. Common stock (INMB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Juda Scott | INMB | Director | Jun 25 '24 | Buy | $7.27 | 5,000 | $36,350.00 | 71,603 | SEC Form 4 |
| Juda Scott | INMB | Director | Apr 19 '24 | Buy | $8.32 | 29,603 | $246,296.96 | 66,603 | SEC Form 4 |
| Moss David J | INMB | CFO, Treasurer & Secretary | Apr 19 '24 | Buy | $8.32 | 18,028 | $149,992.96 | 1,268,179 | SEC Form 4 |
| Tesi Raymond Joseph | INMB | President and CEO | Apr 19 '24 | Buy | $8.32 | 18,028 | $149,992.96 | 1,538,726 | SEC Form 4 |
| Lowdell Mark William | INMB | Chief Scientific Officer | Apr 19 '24 | Buy | $8.32 | 14,423 | $119,999.36 | 1,510,806 | SEC Form 4 |
Latest INmune Bio Inc. Common stock News
INMB Breaking Stock News: Dive into INMB Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
GlobeNewswire
3 days ago
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
Simply Wall St.
15 days ago
Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment
Clinical Trials Arena
a month ago
INmune Bio’s unique Alzheimer’s trial endpoint receives validation
GlobeNewswire
a month ago
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
MT Newswires
2 months ago
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT Newswires
2 months ago
INmune Bio to Join Russell 3000 Index in July
GlobeNewswire
2 months ago
INmune Bio Inc. to Join Russell 3000® Index
Compare INMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMB INmune Bio Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.